Literature DB >> 4250367

Vaccinia virus structural polypeptide derived from a high-molecular-weight precursor: formation and integration into virus particles.

E Katz, B Moss.   

Abstract

Polypeptide 4a, a major vaccinia structural polypeptide which was previously shown to form from a high-molecular-weight precursor is made after the period of viral deoxyribonucleic acid (DNA) synthesis. Pulse-chase experiments demonstrated that a period of 1 to 2 hr is required for a 50% conversion of precursor to product. The rates of incorporation of polypeptides into virus particles were examined. The kinetics of incorporation of labeled 4a and other major structural polypeptides into virus particles were similar, despite the additional time required for the formation of 4a from its precursor. Furthermore, 4a was present exclusively in a particulate form at all times examined. Both observations suggested that cleavage of the precursor occurs after, or immediately prior to, association with developing virus particles. Polypeptide P4a was previously identified as the probable precursor of 4a and is not ordinarily found in detectable amounts in virus particles. Under conditions in which breakdown of P4a was inhibited by adding rifampin or amino acid analogues after the period of viral DNA synthesis, isolated virus particles contained significant amounts of this polypeptide. Further analysis showed that P4a was localized within the virus core, which is also the site of 4a. Synchronization of virus assembly after the removal of rifampin was shown to be useful for studying the integration of polypeptides into a particulate fraction of the cytoplasm.

Entities:  

Mesh:

Substances:

Year:  1970        PMID: 4250367      PMCID: PMC376187     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  21 in total

1.  Sequential protein synthesis following vaccinia virus infection.

Authors:  B Moss; N P Salzman
Journal:  J Virol       Date:  1968-10       Impact factor: 5.103

2.  A procedure for rapid and sensitive staining of protein fractionated by polyacrylamide gel electrophoresis.

Authors:  A Chrambach; R A Reisfeld; M Wyckoff; J Zaccari
Journal:  Anal Biochem       Date:  1967-07       Impact factor: 3.365

3.  Regulation of virus-induced deoxyribonucleases.

Authors:  B R McAuslan; J R Kates
Journal:  Proc Natl Acad Sci U S A       Date:  1966-06       Impact factor: 11.205

4.  Polypeptide cleavages in the formation of poliovirus proteins.

Authors:  M F Jacobson; D Baltimore
Journal:  Proc Natl Acad Sci U S A       Date:  1968-09       Impact factor: 11.205

5.  Rifampicin: a specific inhibitor of vaccinia virus assembly.

Authors:  B Moss; E N Rosenblum; E Katz; P M Grimley
Journal:  Nature       Date:  1969-12-27       Impact factor: 49.962

6.  Analysis of C14-labeled proteins by disc electrophoresis.

Authors:  G Fairbanks; C Levinthal; R H Reeder
Journal:  Biochem Biophys Res Commun       Date:  1965-08-16       Impact factor: 3.575

7.  Studies on "early" enzymes in HeLa cells infected with vaccinia virus.

Authors:  C Jungwirth; W K Joklik
Journal:  Virology       Date:  1965-09       Impact factor: 3.616

8.  Controlled degradation of vaccinia virions in vitro: an electron microscopic study.

Authors:  K B Easterbrook
Journal:  J Ultrastruct Res       Date:  1966-03

9.  Inhibition of HeLa cell protein synthesis by the vaccinia virion.

Authors:  B Moss
Journal:  J Virol       Date:  1968-10       Impact factor: 5.103

10.  Formation of a vaccinia virus structural polypeptide from a higher molecular weight precursor: inhibition by rifampicin.

Authors:  E Katz; B Moss
Journal:  Proc Natl Acad Sci U S A       Date:  1970-07       Impact factor: 11.205

View more
  35 in total

1.  The structure of a putative scaffolding protein of immature poxvirus particles as determined by electron microscopy suggests similarity with capsid proteins of large icosahedral DNA viruses.

Authors:  Jae-Kyung Hyun; Fasséli Coulibaly; Adrian P Turner; Edward N Baker; Andrew A Mercer; Alok K Mitra
Journal:  J Virol       Date:  2007-08-01       Impact factor: 5.103

2.  Biogenesis of poxviruses: analysis of the morphogenetic sequence using a conditional lethal mutant defective in envelope self-assembly.

Authors:  W Stern; B G Pogo; S Dales
Journal:  Proc Natl Acad Sci U S A       Date:  1977-05       Impact factor: 11.205

3.  Inhibition of host protein synthesis by vaccinia virus: fate of cell mRNA and synthesis of small poly (A)-rich polyribonucleotides in the presence of actinomycin D.

Authors:  H Rosemond-Hornbeak; B Moss
Journal:  J Virol       Date:  1975-07       Impact factor: 5.103

4.  Isolation and characterization of a gamma-thiochromanone-4-thiosemicarbazone-resistant mutant of vaccinia virus.

Authors:  E Katz; E Margalith; B Winer
Journal:  Antimicrob Agents Chemother       Date:  1975-01       Impact factor: 5.191

5.  Orthopoxvirus gene expression in Xenopus laevis oocytes: a component of the virion is needed for late gene expression.

Authors:  R F Massung; R W Moyer
Journal:  J Virol       Date:  1990-05       Impact factor: 5.103

6.  Inhibition of a vesicular stomatitis virus mutant by rifampin.

Authors:  M C Moreau
Journal:  J Virol       Date:  1974-09       Impact factor: 5.103

7.  Isolation of an infectious ribonucleoprotein from vesicular stomatitis virus containing an active RNA transcriptase.

Authors:  J F Szilágyi; L Uryvayev
Journal:  J Virol       Date:  1973-02       Impact factor: 5.103

8.  Binding of deoxyribonucleic acid-dependent deoxyribonucleic acid polymerase to poxvirus.

Authors:  K B Tan; B R McAuslan
Journal:  J Virol       Date:  1972-01       Impact factor: 5.103

9.  Phosphoprotein component of vaccinia virions.

Authors:  H Rosemond; B Moss
Journal:  J Virol       Date:  1973-06       Impact factor: 5.103

10.  The Vaccinia virus E8R gene product: a viral membrane protein that is made early in infection and packaged into the virions' core.

Authors:  Laura Doglio; Ario De Marco; Sibylle Schleich; Norbert Roos; Jacomine Krijnse Locker
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.